Publications
Knowledge generated at IrsiCaixa is shared with the scientific community through the publication of articles in high impact scientific journals.
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic.
In danger: HIV vaccine research and development in Europe.
Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients.
Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).
Therapeutic response to an empirical praziquantel treatment in long-staying sub-Saharan African migrants with positive Schistosoma serology and chronic symptoms: a prospective cohort study in Spain.
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial.
Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial.
Non-canonical HIV drug resistance mutations: need to close existing gaps.